(NUVB) Nuvation Bio - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NYSE (USA) | Market Cap: 1.533m USD | Total Return: 162.9% in 12m

Cancer Drugs, Lung Cancer, Solid Tumors
Total Rating 43
Safety 30
Buy Signal 0.09
Biotechnology
Industry Rotation: -3.7
Market Cap: 1.53B
Avg Turnover: 14.1M USD
ATR: 6.20%
Peers RS (IBD): 56.3
Risk 5d forecast
Volatility81.9%
Rel. Tail Risk-16.2%
Reward TTM
Sharpe Ratio1.41
Alpha140.06
Character TTM
Beta0.960
Beta Downside-0.526
Drawdowns 3y
Max DD58.19%
CAGR/Max DD0.64
EPS (Earnings per Share) EPS (Earnings per Share) of NUVB over the last years for every Quarter: "2021-03": -0.12, "2021-06": -0.09, "2021-09": -0.11, "2021-12": -0.12, "2022-03": -0.1, "2022-06": -0.16, "2022-09": -0.12, "2022-12": -0.1, "2023-03": -0.1, "2023-06": -0.09, "2023-09": -0.09, "2023-12": -0.06, "2024-03": -0.07, "2024-06": -0.15, "2024-09": -0.15, "2024-12": -0.1165, "2025-03": -0.134, "2025-06": -0.17, "2025-09": -0.16, "2025-12": -0.11, "2026-03": 0,
EPS CAGR: 76.96%
EPS Trend: 7.2%
Last SUE: 1.22
Qual. Beats: 1
Revenue Revenue of NUVB over the last years for every Quarter: 2021-03: 0, 2021-06: 0, 2021-09: 0, 2021-12: 0, 2022-03: 0, 2022-06: -0.694, 2022-09: -0.191, 2022-12: 0, 2023-03: 0, 2023-06: 0, 2023-09: 0, 2023-12: 0.264, 2024-03: 0.264, 2024-06: 1.435, 2024-09: 0.727, 2024-12: 5.711, 2025-03: 3.084, 2025-06: 4.833, 2025-09: 13.12, 2025-12: 41.865, 2026-03: null,
Rev. CAGR: 194.51%
Rev. Trend: 89.1%
Last SUE: 1.75
Qual. Beats: 8

Warnings

Interest Coverage Ratio -21.8 is critical

Beneish M-Score 0.57 > -1.5 - likely earnings manipulation

Altman Z'' -1.58 < 1.0 - financial distress zone

Volatile

Tailwinds

No distinct edge detected

Description: NUVB Nuvation Bio

Nuvation Bio Inc. (NUVB) is a clinical-stage biopharmaceutical company specializing in oncology drug development. The biotechnology sector is characterized by high research and development costs and lengthy drug approval processes.

Its primary drug candidate is taletrectinib, an ROS1 inhibitor for non-small cell lung cancer. Other pipeline assets include Safusidenib (a mutant isocitrate dehydrogenase 1 inhibitor), NUV-1511 (a chemotherapy agent for solid tumors), and NUV-868 (a bromodomain and extra-terminal inhibitor). The companys business model relies on the successful development and commercialization of new therapeutic compounds.

For more detailed financial and operational insights, consider exploring its profile on ValueRay.

Headlines to Watch Out For
  • Taletrectinib clinical trial results drive stock volatility
  • Safusidenib development progress impacts valuation
  • NUV-1511 and NUV-868 pipeline advancements critical
  • Regulatory approval for oncology drugs creates revenue
  • Competition in oncology drug market affects pricing
Piotroski VR‑10 (Strict) 1.0
Net Income: -204.6m TTM > 0 and > 6% of Revenue
FCF/TA: -0.29 > 0.02 and ΔFCF/TA -5.06 > 1.0
NWC/Revenue: 777.9% < 20% (prev 5.75k%; Δ -4.97k% < -1%)
CFO/TA -0.29 > 3% & CFO -173.4m > Net Income -204.6m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 6.95 > 1.5 & < 3
Outstanding Shares: last quarter (344.3m) vs 12m ago 2.20% < -2%
Gross Margin: 86.58% > 18% (prev 0.12%; Δ 8.65k% > 0.5%)
Asset Turnover: 11.08% > 50% (prev 1.51%; Δ 9.57% > 0%)
Interest Coverage Ratio: -21.84 > 6 (EBITDA TTM -195.8m / Interest Expense TTM 7.65m)
Altman Z'' -1.58
A: 0.82 (Total Current Assets 571.5m - Total Current Liabilities 82.2m) / Total Assets 594.8m
B: -1.88 (Retained Earnings -1.12b / Total Assets 594.8m)
C: -0.29 (EBIT TTM -167.1m / Avg Total Assets 567.7m)
D: 1.06 (Book Value of Equity 305.7m / Total Liabilities 289.1m)
Altman-Z'' Score: -1.58 = D
Beneish M 0.57
DSRI: 0.15 (Receivables 19.4m/16.3m, Revenue 62.9m/8.14m)
GMI: 0.14 (GM 86.58% / 12.30%)
AQI: 1.50 (AQ_t 0.03 / AQ_t-1 0.02)
SGI: 7.73 (Revenue 62.9m / 8.14m)
TATA: -0.05 (NI -204.6m - CFO -173.4m) / TA 594.8m)
Beneish M-Score: 0.57 (Cap -4..+1) = D
What is the price of NUVB shares? As of April 12, 2026, the stock is trading at USD 4.60 with a total of 3,565,930 shares traded.
Over the past week, the price has changed by +3.37%, over one month by -1.92%, over three months by -28.79% and over the past year by +162.86%.
Is NUVB a buy, sell or hold? Nuvation Bio has received a consensus analysts rating of 4.57. Therefore, it is recommended to buy NUVB.
  • StrongBuy: 4
  • Buy: 3
  • Hold: 0
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the NUVB price?
Analysts Target Price 11.6 151.3%
Nuvation Bio (NUVB) - Fundamental Data Overview as of 07 April 2026
P/S = 24.3697
P/B = 5.0141
Revenue TTM = 62.9m USD
EBIT TTM = -167.1m USD
EBITDA TTM = -195.8m USD
Long Term Debt = 47.2m USD (from longTermDebt, last quarter)
Short Term Debt = 7.60m USD (from shortTermDebt, last quarter)
Debt = 54.8m USD (corrected: LT Debt 47.2m + ST Debt 7.60m)
Net Debt = -474.4m USD (recalculated: Debt 54.8m - CCE 529.2m)
Enterprise Value = 1.06b USD (1.53b + Debt 54.8m - CCE 529.2m)
Interest Coverage Ratio = -21.84 (Ebit TTM -167.1m / Interest Expense TTM 7.65m)
EV/FCF = -6.09x (Enterprise Value 1.06b / FCF TTM -173.8m)
FCF Yield = -16.42% (FCF TTM -173.8m / Enterprise Value 1.06b)
 FCF Margin = -276.3% (FCF TTM -173.8m / Revenue TTM 62.9m)
 Net Margin = -325.3% (Net Income TTM -204.6m / Revenue TTM 62.9m)
 Gross Margin = 86.58% ((Revenue TTM 62.9m - Cost of Revenue TTM 8.44m) / Revenue TTM)
Gross Margin QoQ = none% (prev 74.47%)
Tobins Q-Ratio = 1.78 (Enterprise Value 1.06b / Total Assets 594.8m)
Interest Expense / Debt = 12.17% (Interest Expense 6.67m / Debt 54.8m)
Taxrate = 21.0% (US default 21%)
NOPAT = -132.0m (EBIT -167.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.95 (Total Current Assets 571.5m / Total Current Liabilities 82.2m)
Debt / Equity = 0.18 (Debt 54.8m / totalStockholderEquity, last quarter 305.7m)
 Debt / EBITDA = 2.42 (negative EBITDA) (Net Debt -474.4m / EBITDA -195.8m)
 Debt / FCF = 2.73 (negative FCF - burning cash) (Net Debt -474.4m / FCF TTM -173.8m)
 Total Stockholder Equity = 356.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -36.04% (Net Income -204.6m / Total Assets 594.8m)
RoE = -57.48% (Net Income TTM -204.6m / Total Stockholder Equity 356.0m)
RoCE = -41.43% (EBIT -167.1m / Capital Employed (Equity 356.0m + L.T.Debt 47.2m))
 RoIC = -33.25% (negative operating profit) (NOPAT -132.0m / Invested Capital 397.0m)
 WACC = 9.37% (E(1.53b)/V(1.59b) * Re(9.36%) + D(54.8m)/V(1.59b) * Rd(12.17%) * (1-Tc(0.21)))
Discount Rate = 9.36% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 25.42%
 [DCF] Fair Price = unknown (Cash Flow -173.8m)
 EPS Correlation: 7.19 | EPS CAGR: 76.96% | SUE: 1.22 | # QB: 1
Revenue Correlation: 89.15 | Revenue CAGR: 194.5% | SUE: 1.75 | # QB: 8
EPS next Quarter (2026-06-30): EPS=-0.11 | Chg7d=-0.010 | Chg30d=-0.010 | Revisions Net=+0 | Analysts=1
EPS current Year (2026-12-31): EPS=-0.24 | Chg7d=-0.730 | Chg30d=-0.415 | Revisions Net=+0 | Growth EPS=+51.4% | Growth Revenue=+206.0%
EPS next Year (2027-12-31): EPS=-0.14 | Chg7d=-0.015 | Chg30d=-0.045 | Revisions Net=+0 | Growth EPS=+39.6% | Growth Revenue=+49.8%
External Resources
Dataroma Stockcircle